Alnylam Pharmaceuticals Inc.

(ALNY) Trade

By |

Profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Contact Information

Website: www.alnylam.com
Email: investors@alnylam.com
Main Phone: +1 617 551-8200
Address: 675 West Kendall Street
Address 2: Henri A. Termeer Square
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: John M. Maraganore
Employees: 1323
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Contact Information

Website: www.alnylam.com
Email: investors@alnylam.com
Main Phone: +1 617 551-8200
Address: 675 West Kendall Street
Address 2: Henri A. Termeer Square
State: MA
City / Town: Cambridge
Country: US
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: John M. Maraganore
Employees: 1323
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 145.35 $ -0.255 (-0.18%)
Last Price 145.35 Change $ -0.255 Change % -0.18 Tick N/A
Bid 145.20 Bid Size 100.00 Ask 145.49 Ask Size 200.00
Open 146.70 High 148.76 Low 144.42 Prev Close 145.60
Last Trade Volume 311,664 52 Wk Hi 167.34 52 Wk Low 73.32
Market Cap 16.9 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 115,969,783.00 EPS (TTM) -7.58 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 17 96
Number of Buys 4 36
Number of Sells 13 60
Net Activity 233 -22116
Last 10 Buys Shares
Laurie B. Keating 1,000
David E.I. Pyott 1,000
Michael W. Bonney 1,000
David-Alexandre Gros 1,000
David-Alexandre Gros 1,000
Michael W. Bonney 1,000
Steven M. Paul 1,000
John M. Maraganore 1,000
Phillip A. Sharp 1,000
John M. Maraganore 1,000
Last 10 Sell Shares
John K. Clarke 1,000
John K. Clarke 1,000
John K. Clarke 1,000
John K. Clarke 1,000
Yvonne Greenstreet 1,000
Yvonne Greenstreet 1,000
Yvonne Greenstreet 1,000
Yvonne Greenstreet 1,000
Laurie B. Keating 1,000
Laurie B. Keating 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 207 207 207 207
Low Target Price Estimate 95 95 95 95
Mean Target Price Estimate 150.08 150.08 150.08 150.08
Standard Deviation 36.2 36.2 36.2 36.2
Date of Most Recent Estimate 05/07/18 05/07/18 05/07/18 05/07/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 10 10 11 10
Moderate Buy 1 1 1 1
Hold 3 3 3 2
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.73 1.73 1.69 1.64